

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL OPTIONAL
	(Art. 1.01)	(Art. 3)	(Schedule 1)	(Art. 3)	(Art. 3)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPS	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>											
						N/A	N/A					0
						N/A	N/A					0
						N/A	N/A					0
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>											
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						N/A	N/A				
Number of Recipients in aggregate disclosure - Art. 3.02						N/A	N/A					Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						N/A	N/A					N/A

HCOs	International Aids Society (IAS)	Geneva	Switzerland	Avenue de France 23			7,174	N/A	N/A			7,174
								N/A	N/A			0
								N/A	N/A			0
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>											
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						0	0	0	0	0.00	0	Optional
Number of Recipients in aggregate disclosure - Art. 3.02						0	0	0	0	0.00	0	Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						%	0	%	%	%	%	N/A

R & D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											